NICE Single Technology Appraisal Guidance No 193 – Rituximab
for the treatment of relapsed or refractory chronic lymphocytic
This NICE Guidance was
published 28 July 2010. The web reference for the appraisal and
other related documents is: http://guidance.nice.org.uk/TA193
NHSScotland should note
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHS Scotland.
2. NHS Boards should continue to adhere to the
The Scottish Medicines Consortium (SMC)
published a Statement of Advice (591/09) on this medication for
this indication in January 2010. This stated that:
(MabTheraÒ) is accepted for restricted
use within NHS Scotland.
Access the advice of the Scottish Medicines
3. There is no material difference between the
recommendations of the NICE STA and the SMC.
Published Date: 28 July 2010